GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis,” published in the February 2025 ...

FTSE EPRA Nareit Developed Pure Asia Total Return Index USD End Of Day3,290.16‎-0.54% ...

Gastrointestinal (GI) involvement is a common and potentially severe manifestation of eosinophilic granulomatosis with polyangiitis (EGPA), according to study results published in Arthritis Research & ...

Several players from the Brakpan Pool Club will represent the Eastern Gauteng Pool Association (EGPA) at the nationals in Potchefstroom in May. They will compete in several divisions, some in the ...

More common side effects in people receiving Nucala for severe eosinophilic asthma, EGPA, or hypereosinophilic syndrome include: Mild side effects can occur with Nucala use. These side effects can ...